MannKind Corp
General ticker "MNKD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B
MannKind Corp follows the US Stock Market performance with the rate: 61.0%.
Estimated limits based on current volatility of 3.4%: low 6.58$, high 7.05$
Factors to consider:
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.12$, 6.18$]
- 2024-12-30 to 2025-12-30 estimated range: [3.65$, 7.04$]
Financial Metrics affecting the MNKD estimates:
- Negative: Non-GAAP EPS, $ of -0.02 <= 0.10
- Positive: 1.03 < Operating profit margin, % of 4.36
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0.09 <= 0.14
Short-term MNKD quotes
Long-term MNKD plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $75.44MM | $99.77MM | $198.96MM |
| Operating Expenses | $122.46MM | $168.69MM | $190.28MM |
| Operating Income | $-47.02MM | $-68.92MM | $8.68MM |
| Non-Operating Income | $-33.90MM | $-18.48MM | $-19.05MM |
| Interest Expense | $16.58MM | $24.77MM | $25.16MM |
| R&D Expense | $12.31MM | $19.72MM | $31.28MM |
| Income(Loss) | $-80.93MM | $-87.40MM | $-10.38MM |
| Taxes | $0.00MM | $24.77MM | $1.56MM |
| Profit(Loss) | $-80.93MM | $-112.17MM | $-11.94MM |
| Stockholders Equity | $-209.35MM | $-250.54MM | $-246.17MM |
| Inventory | $7.15MM | $21.77MM | $28.55MM |
| Assets | $321.16MM | $295.28MM | $475.20MM |
| Operating Cash Flow | $-61.71MM | $-80.68MM | $34.09MM |
| Capital expenditure | $11.47MM | $7.59MM | $42.44MM |
| Investing Cash Flow | $-151.54MM | $4.87MM | $-1.99MM |
| Financing Cash Flow | $270.27MM | $21.39MM | $136.61MM |
| Earnings Per Share* | $-0.37 | $-0.44 | $-0.04 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.